Pamrevlumab is under investigation in clinical trial NCT00913393 (Study of FibroGen (FG)-3019 in Subjects With Type 2 Diabetes Mellitus and Kidney Disease on ACEi and/or ARB Therapy).
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Diethylstilbestrol | Diethylstilbestrol may increase the thrombogenic activities of Pamrevlumab. |
| Chlorotrianisene | Chlorotrianisene may increase the thrombogenic activities of Pamrevlumab. |
| Conjugated estrogens | Conjugated estrogens may increase the thrombogenic activities of Pamrevlumab. |
| Estrone | Estrone may increase the thrombogenic activities of Pamrevlumab. |
| Estradiol | Estradiol may increase the thrombogenic activities of Pamrevlumab. |
| Dienestrol | Dienestrol may increase the thrombogenic activities of Pamrevlumab. |
| Ethinylestradiol | Ethinylestradiol may increase the thrombogenic activities of Pamrevlumab. |
| Mestranol | Mestranol may increase the thrombogenic activities of Pamrevlumab. |
| Estriol | Estriol may increase the thrombogenic activities of Pamrevlumab. |
| Estrone sulfate | Estrone sulfate may increase the thrombogenic activities of Pamrevlumab. |
| Quinestrol | Quinestrol may increase the thrombogenic activities of Pamrevlumab. |
| Hexestrol | Hexestrol may increase the thrombogenic activities of Pamrevlumab. |
| Tibolone | Tibolone may increase the thrombogenic activities of Pamrevlumab. |
| Synthetic Conjugated Estrogens, A | Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Pamrevlumab. |
| Synthetic Conjugated Estrogens, B | Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Pamrevlumab. |
| Polyestradiol phosphate | Polyestradiol phosphate may increase the thrombogenic activities of Pamrevlumab. |
| Esterified estrogens | Esterified estrogens may increase the thrombogenic activities of Pamrevlumab. |
| Zeranol | Zeranol may increase the thrombogenic activities of Pamrevlumab. |
| Equol | Equol may increase the thrombogenic activities of Pamrevlumab. |
| Promestriene | Promestriene may increase the thrombogenic activities of Pamrevlumab. |
| Methallenestril | Methallenestril may increase the thrombogenic activities of Pamrevlumab. |
| Epimestrol | Epimestrol may increase the thrombogenic activities of Pamrevlumab. |
| Moxestrol | Moxestrol may increase the thrombogenic activities of Pamrevlumab. |
| Estradiol acetate | Estradiol acetate may increase the thrombogenic activities of Pamrevlumab. |
| Estradiol benzoate | Estradiol benzoate may increase the thrombogenic activities of Pamrevlumab. |
| Estradiol cypionate | Estradiol cypionate may increase the thrombogenic activities of Pamrevlumab. |
| Estradiol valerate | Estradiol valerate may increase the thrombogenic activities of Pamrevlumab. |
| Biochanin A | Biochanin A may increase the thrombogenic activities of Pamrevlumab. |
| Formononetin | Formononetin may increase the thrombogenic activities of Pamrevlumab. |
| Estetrol | Estetrol may increase the thrombogenic activities of Pamrevlumab. |
| Cetuximab | The risk or severity of adverse effects can be increased when Cetuximab is combined with Pamrevlumab. |
| Human immunoglobulin G | The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Pamrevlumab. |
| Omalizumab | The risk or severity of adverse effects can be increased when Omalizumab is combined with Pamrevlumab. |
| Adalimumab | The risk or severity of adverse effects can be increased when Adalimumab is combined with Pamrevlumab. |
| Abciximab | The risk or severity of adverse effects can be increased when Abciximab is combined with Pamrevlumab. |
| Gemtuzumab ozogamicin | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Pamrevlumab. |
| Indium In-111 satumomab pendetide | The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Pamrevlumab. |
| Infliximab | The risk or severity of adverse effects can be increased when Infliximab is combined with Pamrevlumab. |
| Trastuzumab | The risk or severity of adverse effects can be increased when Trastuzumab is combined with Pamrevlumab. |
| Rituximab | The risk or severity of adverse effects can be increased when Rituximab is combined with Pamrevlumab. |
| Basiliximab | The risk or severity of adverse effects can be increased when Basiliximab is combined with Pamrevlumab. |
| Muromonab | The risk or severity of adverse effects can be increased when Muromonab is combined with Pamrevlumab. |
| Digoxin Immune Fab (Ovine) | The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Pamrevlumab. |
| Ibritumomab tiuxetan | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Pamrevlumab. |
| Tositumomab | The risk or severity of adverse effects can be increased when Tositumomab is combined with Pamrevlumab. |
| Alemtuzumab | The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Pamrevlumab. |
| Capromab pendetide | The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Pamrevlumab. |
| Efalizumab | The risk or severity of adverse effects can be increased when Efalizumab is combined with Pamrevlumab. |
| Antithymocyte immunoglobulin (rabbit) | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Pamrevlumab. |
| Natalizumab | The risk or severity of adverse effects can be increased when Natalizumab is combined with Pamrevlumab. |
| Palivizumab | The risk or severity of adverse effects can be increased when Palivizumab is combined with Pamrevlumab. |
| Daclizumab | The risk or severity of adverse effects can be increased when Daclizumab is combined with Pamrevlumab. |
| Bevacizumab | The risk or severity of adverse effects can be increased when Bevacizumab is combined with Pamrevlumab. |
| Technetium Tc-99m arcitumomab | The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Pamrevlumab. |
| Eculizumab | The risk or severity of adverse effects can be increased when Eculizumab is combined with Pamrevlumab. |
| Panitumumab | The risk or severity of adverse effects can be increased when Panitumumab is combined with Pamrevlumab. |
| Ranibizumab | The risk or severity of adverse effects can be increased when Ranibizumab is combined with Pamrevlumab. |
| Galiximab | The risk or severity of adverse effects can be increased when Galiximab is combined with Pamrevlumab. |
| Pexelizumab | The risk or severity of adverse effects can be increased when Pexelizumab is combined with Pamrevlumab. |
| Afelimomab | The risk or severity of adverse effects can be increased when Afelimomab is combined with Pamrevlumab. |
| Epratuzumab | The risk or severity of adverse effects can be increased when Epratuzumab is combined with Pamrevlumab. |
| Bectumomab | The risk or severity of adverse effects can be increased when Bectumomab is combined with Pamrevlumab. |
| Oregovomab | The risk or severity of adverse effects can be increased when Oregovomab is combined with Pamrevlumab. |
| IGN311 | The risk or severity of adverse effects can be increased when IGN311 is combined with Pamrevlumab. |
| Adecatumumab | The risk or severity of adverse effects can be increased when Adecatumumab is combined with Pamrevlumab. |
| Labetuzumab | The risk or severity of adverse effects can be increased when Labetuzumab is combined with Pamrevlumab. |
| Matuzumab | The risk or severity of adverse effects can be increased when Matuzumab is combined with Pamrevlumab. |
| Fontolizumab | The risk or severity of adverse effects can be increased when Fontolizumab is combined with Pamrevlumab. |
| Bavituximab | The risk or severity of adverse effects can be increased when Bavituximab is combined with Pamrevlumab. |
| CR002 | The risk or severity of adverse effects can be increased when CR002 is combined with Pamrevlumab. |
| Rozrolimupab | The risk or severity of adverse effects can be increased when Rozrolimupab is combined with Pamrevlumab. |
| Girentuximab | The risk or severity of adverse effects can be increased when Girentuximab is combined with Pamrevlumab. |
| Obiltoxaximab | The risk or severity of adverse effects can be increased when Obiltoxaximab is combined with Pamrevlumab. |
| XTL-001 | The risk or severity of adverse effects can be increased when XTL-001 is combined with Pamrevlumab. |
| NAV 1800 | The risk or severity of adverse effects can be increased when NAV 1800 is combined with Pamrevlumab. |
| Briakinumab | The risk or severity of adverse effects can be increased when Briakinumab is combined with Pamrevlumab. |
| Otelixizumab | The risk or severity of adverse effects can be increased when Otelixizumab is combined with Pamrevlumab. |
| AMG 108 | The risk or severity of adverse effects can be increased when AMG 108 is combined with Pamrevlumab. |
| Iratumumab | The risk or severity of adverse effects can be increased when Iratumumab is combined with Pamrevlumab. |
| Enokizumab | The risk or severity of adverse effects can be increased when Enokizumab is combined with Pamrevlumab. |
| Ramucirumab | The risk or severity of adverse effects can be increased when Ramucirumab is combined with Pamrevlumab. |
| Farletuzumab | The risk or severity of adverse effects can be increased when Farletuzumab is combined with Pamrevlumab. |
| Veltuzumab | The risk or severity of adverse effects can be increased when Veltuzumab is combined with Pamrevlumab. |
| Ustekinumab | The risk or severity of adverse effects can be increased when Ustekinumab is combined with Pamrevlumab. |
| Trastuzumab emtansine | The risk or severity of adverse effects can be increased when Trastuzumab emtansine is combined with Pamrevlumab. |
| PRO-542 | The risk or severity of adverse effects can be increased when PRO-542 is combined with Pamrevlumab. |
| TNX-901 | The risk or severity of adverse effects can be increased when TNX-901 is combined with Pamrevlumab. |
| Inotuzumab ozogamicin | The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Pamrevlumab. |
| RI 624 | The risk or severity of adverse effects can be increased when RI 624 is combined with Pamrevlumab. |
| Stamulumab | The risk or severity of adverse effects can be increased when MYO-029 is combined with Pamrevlumab. |
| CT-011 | The risk or severity of adverse effects can be increased when CT-011 is combined with Pamrevlumab. |
| Leronlimab | The risk or severity of adverse effects can be increased when Leronlimab is combined with Pamrevlumab. |
| Glembatumumab vedotin | The risk or severity of adverse effects can be increased when Glembatumumab vedotin is combined with Pamrevlumab. |
| Olaratumab | The risk or severity of adverse effects can be increased when Olaratumab is combined with Pamrevlumab. |
| IPH 2101 | The risk or severity of adverse effects can be increased when IPH 2101 is combined with Pamrevlumab. |
| TB-402 | The risk or severity of adverse effects can be increased when TB-402 is combined with Pamrevlumab. |
| Caplacizumab | The risk or severity of adverse effects can be increased when Caplacizumab is combined with Pamrevlumab. |
| IMC-1C11 | The risk or severity of adverse effects can be increased when IMC-1C11 is combined with Pamrevlumab. |
| Eldelumab | The risk or severity of adverse effects can be increased when Eldelumab is combined with Pamrevlumab. |
| Lumiliximab | The risk or severity of adverse effects can be increased when Lumiliximab is combined with Pamrevlumab. |